ArticlePharmacoEconomics2017
How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.
Article in PharmacoEconomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Methods for Analysing Patient-Level Utility Data: Insights from the Literature Review and Recent NICE Technology Appraisals.PharmacoEconomics · 2026Review
- A Scoping Review of Methods for Extrapolating Costs and Effects in Economic Evaluations of Remote Monitoring.PharmacoEconomics - open · 2026Review
- Retrospective Analysis of Burden of Illness of Congenital Pulmonary Valve Disease in a Large, Commercially Insured US Population.Journal of health economics and outcomes research · 2026Article
- Friedreich's ataxia patient pathway in Europe.Frontiers in health services · 2026Article
- Time trends of variability in disease activity in systemic lupus erythematosus.Lupus science & medicine · 2025Article
- Methods for extrapolating costs and effects in economic evaluations of telehealth interventions: a scoping review protocol.BMJ open · 2024Article
- Integrating hypertension detection and management in HIV care in South Africa: protocol for a stepped-wedged cluster randomized effectiveness-implementation hybrid trial.Implementation science communications · 2024Article
- Article
- Cost effectiveness and return on investment analysis for surgical care in a conflict-affected region of Sudan.PLOS global public health · 2024Article
- Impact of specialist ataxia centres on health service resource utilisation and costs across Europe: cross-sectional survey.Orphanet journal of rare diseases · 2023Article
- Economic analysis of early intervention for autistic children: findings from four case studies in England, Ireland, Italy, and Spain.European psychiatry : the journal of the Association of European Psychiatrists · 2023Observational
- Lifetime Costs of Surviving Cancer-A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study.International journal of environmental research and public health · 2020Article
- Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.Health and quality of life outcomes · 2019Article
- Cancer Incidence Trends From 1999 to 2015 And Contributions Of Various Cancer Types To The Overall Burden: Projections To 2030 And Extrapolation Of Economic Burden In Saudi Arabia.Cancer management and research · 2019Article
- The Burden, Future Trends, And Economic Impact Of Lung Cancer In Saudi Arabia.ClinicoEconomics and outcomes research : CEOR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Costs and utilities are key inputs into any cost-effectiveness analysis. Their estimates are typically derived from individual patient-level data collected as part of clinical studies the follow-up duration of which is often too short to allow a robust quantification of the likely costs and benefits a technology will yield over the patient's entire lifetime. In the absence of long-term data, some form of temporal extrapolation-to project short-term evidence over a longer time horizon-is required. Temporal extrapolation inevitably involves assumptions regarding the behaviour of the quantities of interest beyond the time horizon supported by the clinical evidence. Unfortunately, the implications for decisions made on the basis of evidence derived following this practice and the degree of uncertainty surrounding the validity of any assumptions made are often not fully appreciated. The issue is compounded by the absence of methodological guidance concerning the extrapolation of non-time-to-event outcomes such as costs and utilities. This paper considers current approaches to predict long-term costs and utilities, highlights some of the challenges with the existing methods, and provides recommendations for future applications. It finds that, typically, economic evaluation models employ a simplistic approach to temporal extrapolation of costs and utilities. For instance, their parameters (e.g. mean) are typically assumed to be homogeneous with respect to both time and patients' characteristics. Furthermore, costs and utilities have often been modelled to follow the dynamics of the associated time-to-event outcomes. However, cost and utility estimates may be more nuanced, and it is important to ensure extrapolation is carried out appropriately for these parameters.
Indexed as
Identifiers
28470594What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.